Boston Scientific (NYSE:BSX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a ...
Hosted on MSN1mon
Globus Medical strengthens SCS market position with $250m Nevro dealBoston Scientific’s Wavewriter spinal cord stimulator systems, for example, gained access to a wider market after winning FDA approval for non-surgical back pain in February 2024. Looking ahead ...
StockNews.com upgraded shares of Boston Scientific (NYSE:BSX – Free Report) from a hold rating to a buy rating in a research report sent to investors on Friday. A number of other equities analysts ...
Boston Scientific Corporation develops ... neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback